Trial Profile
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Parathyroid hormone (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Registrational
- Acronyms TOP
- Sponsors NPS Pharmaceuticals
- 19 Apr 2014 New trial record
- 11 Aug 2008